<DOC>
	<DOCNO>NCT01988636</DOCNO>
	<brief_summary>Background : - Malaria cause small germ carry mosquito . People get malaria infect mosquito bite . Malaria destroy red blood cell reduce oxygen blood . Most malaria mild , severe malaria kill least 660,000 people year . About 75 % child Sub-Saharan Africa , age 5 . Researchers want find safe vaccine help prevent malaria . Objectives : - To see new malaria vaccine well tolerate effective . Eligibility : - Healthy adult 18 35 year old pregnant live Mali . Design : - Participants screen medical history , physical exam , blood test . They also ECG . Soft electrodes stuck skin . A machine record heart electrical signal . - Study participation last 1 year . - Participants randomly place 5 group . Some get 2 dos PfSPZ vaccine week apart ; get 3 5 dos vaccine ; get 3 5 dos placebo . - Doses give needle arm directly bloodstream . Then participants must stay clinic 2 hour . - After dose , participant return clinic several time blood test physical exam . - A week first dose 2 week last , participant take full course anti-malaria drug . - If participant get malaria study , take another course anti-malaria drug .</brief_summary>
	<brief_title>Study Safety Effectiveness Intravenous Immunization With PfSPZ Vaccine Healthy African Adults</brief_title>
	<detailed_description>For decade know human protect malaria repeat immunization radiation-attenuated sporozoite . Traditionally , sporozoite administer expose vaccinee least 1000 bite sporozoite-infected irradiated mosquito , approach unsuitable mass vaccination campaign . Recently , Sanaria Inc. 1 develop process manufacturing , compliance current Good Manufacturing Practices ( cGMPs ) aseptic , purify , radiation attenuate cryopreserved sporozoite wellcharacterized isolate P. falciparum . This product , call PfSPZ Vaccine , administer needle syringe . Previous study conduct Vaccine Research Center , National Institutes Health ( NIH ) Navy establish IV administration PfSPZ Vaccine induce sterile protection control human malaria infection ( CHMI ) homologous strain P. falciparum 100 % malaria na ( SqrRoot ) individual . The next logical step test safety immunogenicity PfSPZ Vaccine malaria experience individual . As exploratory objective , study collect initial data find vaccine protect naturally occur infection . Here , propose randomize double blind control trial ass safety immunogenicity IV administration PfSPZ Vaccine African adult . Subjects recruit rural village Mali . The study conduct collaboration among Malaria Research Training Center ( MRTC , Mali ) , Laboratory Malaria Immunology Vaccinology ( LMIV ) National Institute Allergy Infectious Diseases ( NIAID ) , Sanaria , Inc. Group 1 ( n=12 ) , receive 135,000 PfSPZ Vaccine , follow 270,000 PfSPZ Vaccine 2 week later safety purpose . An independent Data Safety Monitoring Board ( DSMB ) determine whether safe proceed 270,000 PfSPZ Vaccine . At Study Week 4 , Group 4 ( n=50 ) receive first 5 dos 270,000 PfSPZ Vaccine give 4 , 8 , 12 , 16 , 24 week , alongside Group 5 ( n=50 ) receive similar volume placebo . Safety data collect defined time point immunization . From Week 28 Week 48 subject monitor parasitemia detect slide microscopy every 14 day passive case detection .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA The subject must satisfy follow criterion eligible study : 1 . Signed informed consent form ( ICF ) 2 . Aged 18 35 year 3 . Long term resident study site ( live least 4 year ) 4 . Willingness remain resident village abstain travel prolong period study 5 . Willingness undergo HIV test test need determine exclusion . ( In case positive test , clinician issue referral letter participant guide him/her HIV specialist care appropriate management follow ) . 6 . Willingness take curative antimalarial regimen prescribe investigator 7 . Willingness provide blood safety data . 8 . For female : agreement use reliable contraception ( set trial take place document depot injection contraceptive , surgical sterilization ; implant device ( write evidence provide appropriately trained physician ) consider reliable contraception ) duration vaccination phase ( i.e. , 1 month prior first vaccination 1 month last vaccination ) 9 . For female : negative pregnancy test screen vaccination ; woman find pregnant give subsequent dos follow safety reason EXCLUSION CRITERIA 1 . Use antimalarial ( prescribed investigator ) systemic antibiotic know antimalarial activity within 30 day prior first vaccine dose ( e.g . TrimethoprimSulfamethoxazole , Doxycycline , Tetracycline , Clindamycin , Erythromycin , Fluoroquinolones , Azithromycin ) 2 . Receipt investigational product 30 day precede enrolment , plan receipt study period 3 . Prior receipt malaria vaccine candidate 4 . Recurrent , severe infection malaria , chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) 5 . Use immunoglobulins blood product within 3 month prior enrolment 6 . A history allergic disease significant reaction mosquito bite 7 . Known allergy contraindication Artemether/Lumefantrine , Atovaquone/Proguanil , : 1 . Concurrent medication Neuroleptics , Antidepressants ( i.e. , Imipramine , Amitryptilline , Clomipramine others ) , Drugs use treat tuberculosis , include Rifampicin Rifabutine , Macrolide antibiotic ( i.e. , Erythromycin , Clarithromycin , Azithromycin , Roxitromycin ) , Fluoroquinolones ( i.e. , Ciprofloxacin , Moxifloxacin , Levofloxacin ) , Antimykotics ( i.e. , Ketoconazole , Itraconazole ) , Cimetidine , Class IA class III antiarrhythmic ( i.e. , Quinidine , Ajmalin , Disopyramid , Amiodaron , Sotalol ) , Flecainid , Metoprolol , Cisaprid , Terfenadin , Astemizole , Metoclopramide 2 . Renal impairment 3 . Symptoms low potassium , and/or low magnesium 4 . A family history sudden cardiac death , opinion investigator cause preexist arrhythmia 5 . Known diagnosis family history long QT syndrome 6 . Heart disease ( i.e. , heart failure , arrhythmia ) 8 . History cancer ( except basal cell carcinoma ) 9 . History serious psychiatric condition may affect participation study 10 . If female : currently pregnant , lactate / breastfeed 11 . Any serious chronic illness require hospital specialist supervision diabetes mellitus type 2 . 12 . Suspected known current alcohol abuse define alcohol intake great 60 g per day 13 . Suspected known inject drug abuse 5 year precede enrolment 14 . Any confirmed suspected immunosuppressive immune modulate disorder ( i.e. , asplenia , lupus , rheumatoid arthritis , vasculitis , sclerodermia , diabetes mellitus ) 15 . Hematuria , proteinuria , glucosuria detect urine dip stick level define Appendix F 16 . Any clinically significant abnormality 12 lead ECG 17 . Seropositive Hepatitis B surface antigen ( HBsAg ) 18 . Seropositive Hepatitis C virus ( antibody HCV ) 19 . Seropositive HIV 20 . Seropositive Syphilis 21 . Sickle cell trait carriage sickle cell disease 22 . Any clinically significant abnormal find biochemistry hematology blood test , urinalysis clinical examination 23 . Any significant disease , disorder finding , opinion investigator , may significantly increase risk subject participation study , affect ability subject participate study impair interpretation study data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 20, 2015</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Double Blinded</keyword>
	<keyword>Mali</keyword>
	<keyword>Malaria</keyword>
	<keyword>Transmission</keyword>
</DOC>